Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
cyclophosphamide
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(66)
News
Trials
Company:
Generic mfg.
Drug class:
Alkylating agent
Related drugs:
‹
trabectedin (24)
STAR-001 (16)
lomustine (15)
carmustine (14)
lurbinectedin (11)
melphalan (9)
chlorambucil (7)
melphalan flufenamide (7)
temozolomide gel (7)
procarbazine hydrochloride (4)
OBI-3424 (4)
D19466 (4)
mitomycin (3)
thiotepa (3)
bendamustine RTD (2)
LP-284 (2)
fotemustine (2)
busulfan (2)
VAL-083 (2)
ACHM-025 (1)
BYON4413 (1)
FGX15-147-based ADC (1)
treosulfan (1)
IMGS-101 (1)
bendamustine rapid infusion (0)
ranimustine (0)
carmustine implant (0)
TL-118 (0)
altretamine (0)
mechlorethamine (0)
satraplatin (0)
PR104 (0)
pegylated liposomal mitomycin-c prodrug (0)
QBS72S (0)
mechlorethamine gel (0)
EX-204 (0)
captisol-enabled melphalan (0)
cyclophosphamide intravenous (0)
D 19575 (0)
CB1954 (0)
trabectedin (24)
STAR-001 (16)
lomustine (15)
carmustine (14)
lurbinectedin (11)
melphalan (9)
chlorambucil (7)
melphalan flufenamide (7)
temozolomide gel (7)
procarbazine hydrochloride (4)
OBI-3424 (4)
D19466 (4)
mitomycin (3)
thiotepa (3)
bendamustine RTD (2)
LP-284 (2)
fotemustine (2)
busulfan (2)
VAL-083 (2)
ACHM-025 (1)
BYON4413 (1)
FGX15-147-based ADC (1)
treosulfan (1)
IMGS-101 (1)
bendamustine rapid infusion (0)
ranimustine (0)
carmustine implant (0)
TL-118 (0)
altretamine (0)
mechlorethamine (0)
satraplatin (0)
PR104 (0)
pegylated liposomal mitomycin-c prodrug (0)
QBS72S (0)
mechlorethamine gel (0)
EX-204 (0)
captisol-enabled melphalan (0)
cyclophosphamide intravenous (0)
D 19575 (0)
CB1954 (0)
›
Associations
(66)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Breast Cancer
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
No biomarker
Burkitt Lymphoma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Retinoblastoma
No biomarker
Retinoblastoma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
No biomarker
Medulloblastoma
No biomarker
Medulloblastoma
cisplatin + cyclophosphamide + vincristine
Sensitive: A2 - Guideline
cisplatin + cyclophosphamide + vincristine
Sensitive
:
A2
cisplatin + cyclophosphamide + vincristine
Sensitive: A2 - Guideline
cisplatin + cyclophosphamide + vincristine
Sensitive
:
A2
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
cyclophosphamide + etoposide IV
Sensitive
:
A2
cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
cyclophosphamide + etoposide IV
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
No biomarker
Salivary Gland Cancer
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A2
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A2 - Guideline
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
No biomarker
T Acute Lymphoblastic Leukemia
No biomarker
T Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
Sensitive: A2 - Guideline
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
Sensitive
:
A2
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
Sensitive: A2 - Guideline
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
cyclophosphamide + ifosfamide + etoposide IV + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + ifosfamide + etoposide IV + topotecan
Sensitive
:
A2
cyclophosphamide + ifosfamide + etoposide IV + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + ifosfamide + etoposide IV + topotecan
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive
:
A2
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
gemcitabine + docetaxel + cyclophosphamide
Sensitive: A2 - Guideline
gemcitabine + docetaxel + cyclophosphamide
Sensitive
:
A2
gemcitabine + docetaxel + cyclophosphamide
Sensitive: A2 - Guideline
gemcitabine + docetaxel + cyclophosphamide
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
carboplatin + cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
carboplatin + cyclophosphamide + etoposide IV
Sensitive
:
A2
carboplatin + cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
carboplatin + cyclophosphamide + etoposide IV
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
carboplatin + cyclophosphamide
Sensitive: A2 - Guideline
carboplatin + cyclophosphamide
Sensitive
:
A2
carboplatin + cyclophosphamide
Sensitive: A2 - Guideline
carboplatin + cyclophosphamide
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
cyclophosphamide + etoposide IV
Sensitive
:
A2
cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
cyclophosphamide + etoposide IV
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
cyclophosphamide + vinorelbine tartrate
Sensitive: A2 - Guideline
cyclophosphamide + vinorelbine tartrate
Sensitive
:
A2
cyclophosphamide + vinorelbine tartrate
Sensitive: A2 - Guideline
cyclophosphamide + vinorelbine tartrate
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + cyclophosphamide + ifosfamide + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + cyclophosphamide + ifosfamide + vincristine
Sensitive
:
A2
doxorubicin hydrochloride + cyclophosphamide + ifosfamide + vincristine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + cyclophosphamide + ifosfamide + vincristine
Sensitive
:
A2
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
cyclophosphamide + topotecan
Sensitive: A2 - Guideline
cyclophosphamide + topotecan
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login